Detalhe da pesquisa
1.
Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study.
Clin Exp Rheumatol
; 2024 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38436358
2.
Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
World J Urol
; 41(4): 1069-1075, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36929410
3.
Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
Wien Med Wochenschr
; 170(5-6): 132-140, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31654156
4.
Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Clin Exp Rheumatol
; 34(3): 489-99, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26966919
5.
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
BMC Musculoskelet Disord
; 16: 176, 2015 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26228643
6.
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
BMC Musculoskelet Disord
; 15: 14, 2014 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-24410774
7.
Rhinoviruses as an underestimated cause of influenza-like illness in pregnancy during the 2009-2010 influenza pandemic.
J Med Virol
; 85(8): 1473-7, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23722328
8.
Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
Clin Exp Rheumatol
; 36(5): 935-936, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29600933
9.
Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Clin Rheumatol
; 42(9): 2321-2334, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314665
10.
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
Clin Rheumatol
; 41(8): 2361-2373, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35536413
11.
[Not Available]. / ACCOUCHEMENT, DÉLIVRANCE ET SUITES DE COUCHES NORMALES.
Rev Prat
; 66(6 Suppl): e247-54, 2016 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-27538334
12.
Survey of the therapeutic management of rheumatoid arthritis in France: the OPALE study.
Clin Exp Rheumatol
; 28(3): 325-32, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20460034
13.
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
Clin Rheumatol
; 38(11): 3049-3059, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31300979
14.
Two-year abatacept retention rate in clinical practice in the French ACTION cohort.
Joint Bone Spine
; 86(6): 753-759, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31352138
15.
Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Clin Rheumatol
; 38(5): 1535, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30972577
16.
Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Clin Rheumatol
; 38(5): 1413-1424, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30790095
17.
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
RMD Open
; 3(1): e000345, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28243468
18.
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
RMD Open
; 3(2): e000538, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435360
19.
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Joint Bone Spine
; 84(5): 571-576, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28043761
20.
Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.
RMD Open
; 2(1): e000228, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26925253